Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Thomas Coats, PhD, Royal Devon University Hospital Foundation Trust, Exeter, UK, discusses the future of artificial intelligence (AI) models in the field of hematology. Using…
AbstractBackground. Few studies have evaluated mental health disorders comprehensively among patients with prostate cancer on long-term follow-up. The prim
Experiencing guilt after cancer treatment may sound unexpected, but it’s actually quite common. Clinical psychologist Catherine Powers, Ph.D., and senior social work counselor Kendolyn Shankle…
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
A recent study may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients.
An abstract is unavailable.
A higher level of MRD before transplant is associated with a higher risk of relapse and death in patients with FLT3-ITD AML, data suggest.
Detailed information about the Translational Research Training in Hematology (TRTH) application process
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
A biologics license application has been accepted by the FDA for subcutaneous nivolumab to treat adult patients eligible for approved solid tumor nivolumab indications